{
  "authorized_claims": [
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Vitamin K contributes to the maintenance of normal bones.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of vitamin K\" as referred to in the Annex to Reg 1924/2006"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Vitamin K contributes to normal blood clotting.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of vitamin K\" as referred to in the Annex to Reg 1924/2006"
    },
    {
      "market": "ANVISA",
      "framework_reference": "IN 28/2018 Anexo V alegação funcional",
      "claim_verbatim": "A vitamina K auxilia na coagulação do sangue.",
      "authorization_date": "2018",
      "conditions": "IN 28/2018 Anexo V: alegação restrita a suplementos cujo aporte diário do nutriente atenda à quantidade mínima do Anexo II"
    }
  ],
  "slug": "vitamin-k2",
  "name": "Vitamin K2 · Menaquinone (MK-4 · MK-7)",
  "alternate_names": [
    "Menaquinone-7",
    "MK-7",
    "MK-4",
    "Menatetrenone"
  ],
  "mechanism": [
    "Cofactor for γ-glutamyl carboxylase activating Gla-proteins",
    "Carboxylates osteocalcin (bone matrix incorporation of calcium)",
    "Carboxylates matrix Gla protein (inhibits vascular calcification)"
  ],
  "target": [
    "Osteocalcin γ-carboxylation",
    "Matrix Gla protein",
    "Vascular calcification"
  ],
  "use_case": [
    "bone health framework",
    "arterial calcification mitigation adjunct",
    "maintenance of normal blood coagulation when K1 intake low"
  ],
  "body_system": [
    "MUSCULOSKELETAL",
    "CARDIO"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 2,
  "dosage_range": "90 μg/day NRV (men) · 90 μg/day (women); typical MK-7 supplement dose 90-200 μg/day. Geleijnse 2004 PMID 15514282 J Nutr Rotterdam Study cohort (n = 4,807) reported the highest tertile of dietary menaquinone intake associated with lower CHD mortality (RR 0.43, 95% CI 0.24-0.77) and severe aortic calcification (OR 0.48). Rønn 2021 PMID 33030563 Osteoporos Int 3-year RCT (n = 142 postmenopausal women with osteopenia, 375 μg MK-7/day + D3 + Ca) found osteocalcin carboxylation improved but bone mineral density and microarchitecture did not differ vs. placebo — honest mixed signal",
  "safety_notes": "Contraindicated in patients on vitamin K antagonist therapy (warfarin); inform clinician before starting MK-7 if on anticoagulants; otherwise excellent safety profile within typical supplement doses",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · NDI for MK-7 cleared",
    "efsa": "Authorized claims Reg 432/2012 bone maintenance + normal coagulation (vitamin K source threshold required); NRV 75 μg",
    "anvisa": "RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: \"A vitamina K auxilia na coagulação do sangue.\" Bone claim not separately authorized — vitamina K within bone-health stack must rely on Anexo V coagulação claim only"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/vitamin-k2/",
  "related_goal_slugs": [
    "joint-bone",
    "heart-health",
    "menopause-support",
    "longevity-stack"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus",
    "menopause"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}